Nivolumab Plus Relatlimab Yields Durable Responses After Progression of Advanced Melanoma
Source: Cancer Therapy Advisor, February 2023
Nivolumab plus relatlimab can produce durable responses in patients with advanced melanoma whose disease progressed on anti-PD-1/PD-L1 regimens, according to findings published in the Journal of Clinical Oncology.
These results come from RELATIVITY-020 (ClinicalTrials.gov identifier: NCT01968109), a phase 1/2a trial designed to evaluate relatlimab alone or in combination with nivolumab in patients with advanced solid tumors.
P
art D of the trial was designed to assess nivolumab and relatlimab in patients with advanced melanoma who had progression during, or within 3 months of, anti-PD-1/PD-L1-containing regimens. Patients in part D1 had received 1 prior anti-PD-1 regimen, and patients in part D2 had received 2 or more anti-PD-1 or anti-PD-L1 regimens.